CYCytokinetics CYTK · NASDAQ
$63.31 +3.31% (+$2.03)
- Market cap
- $8.80B
- Enterprise value
- $9.82B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 124.0x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -39.3%
- Gross margin
- 85.0%
- Net margin
- -1,259.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.36
- Free float
- 96.5%
About the company
Cytokinetics, Incorporated is an American biotechnology company specializing in the development of therapeutic approaches aimed at improving muscle function in patients with heart and muscle diseases. The company develops innovative drug candidates targeting the regulation of muscle proteins, which can help treat conditions such as heart failure, amyotrophic lateral sclerosis (ALS), and other muscle disorders. Cytokinetics focuses on providing new treatment options for patients for whom current therapies are insufficiently effective.
Sector
Healthcare
Industry
Biotechnology
CEO
Robert I. Blum
Employees
673
Headquarters
South San Francisco
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Analysts expect revenue to grow by 74% this fiscal year.
- What to watch: Revenue fell by 2.4% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: It passes only 1 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
- What speaks for it: The price moves less than the market (beta 0.36).
Statements
Every number